v3.26.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities    
Net loss $ (5,826,243) $ (1,986,153)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization and depreciation 172,554 197,355
Stock-based compensation 1,054,167 906,048
Valuation adjustments for excess or obsolete inventory 1,000 7,500
Amortization of deferred offering costs 192,647
Non-cash lease expense 88,444 83,187
Fair value change in warrant liability (620,171) (1,099,421)
Debt termination costs reclassed to financing activities 141,416
Change in assets and liabilities:    
Accounts receivable 165,840 176,636
Inventory (64,449) 729,952
Prepaid expenses (177,568) (16,902)
Accounts payable (93,078) (286,960)
Accrued expenses, operating leases and other liabilities (226,831) (356,905)
Net cash used in operating activities (5,526,335) (1,311,600)
Investing activities    
Purchase of property and equipment (98,929) (71,135)
Net cash used in investing activities (98,929) (71,135)
Financing activities    
Proceeds from issuance of common stock attributed to equity financings 1,029,386 9,614,037
Issuance costs related to equity financings (10,777) (1,231,873)
Financing costs in connection with debt facility (297,942)
Deferred issuance costs in connection with at-the-market offering program (22,920)
Exercise of warrants 174,374
Share repurchases for the payment of employee taxes (67,585) (121,846)
Net cash provided by financing activities 1,102,478 7,962,376
Net (decrease) increase in cash and cash equivalents (4,522,786) 6,579,641
Cash and cash equivalents at beginning of period 6,570,382 1,460,042
Cash and cash equivalents at end of period 2,047,596 8,039,683
Supplemental non-cash financing and investing transactions:    
Change in unpaid issuance costs 11,575
Modification of right-of-use asset and associated lease liability 111,898
Purchased property and equipment in accounts payable 7,228
Cashless exercise of warrants 87,188
Reclass of warrant liability to equity upon exercise 342,918
Amortization of deferred offering costs related to equity financings $ 1,219